Background <p>Glioblastoma (GBM) remains uniformly lethal due to pronounced intratumoral heterogeneity and a highly immunosuppressive microenvironment that limits the efficacy of targeted therapies.</p> Methods <p>We engineered chimeric antigen receptor (CAR) T cells targeting Epidermal Growth Factor Receptor variant III (EGFRvIII) and armored them with a single-chain interleukin-12 (scIL12) payload. These cells were tested in syngeneic, orthotopic GBM mouse models exhibiting…
IL-12-secreting CAR-T cells reprogram the tumor microenvironment and improve efficacy against heterogeneous models of glioblastoma
Journal for ImmunoTherapy of Cancer | | Shen, S., Mohan, A. A., Hotchkiss, K. M., Cook, S., Patel, K., Moelker, E., Puviindran, B., Gonzalez, A. T., Zaidi, S., Spellicy, S., Schwartz, A., Suryadevara, C., Wilkinson, D., Ayasoufi, K., Fecci, P. E., Sanchez-Perez, L., Sampson, J., Patel, A.
Topics: lung-cancer, brain-cancer, immunotherapy, new-technology
Read the full article at Journal for ImmunoTherapy of Cancer